Managing indolent lymphoma collaboratively

Aug. 08, 2022


Mayo Clinic Comprehensive Cancer Center hematologist and oncologist Jose (J.C.) C. Villasboas Bisneto, M.D., discusses follicular lymphoma and other indolent B-cell non-Hodgkin’s lymphomas. For many of these slow-growing diseases, cure is not the goal. Rather, a patient's care team must remain flexible and nimble in the treatment plan to manage the disease.

Dr. Villasboas aims to take a collaborative approach with his patients' care teams at home to ensure long-term disease management with the most advanced therapies. Examples include immunotherapies such as CAR-T cell therapy, which is already approved by the FDA for patients with relapsed follicular lymphoma.